Adjuvant chemoradiation for gastric cancer: multicentric study of the Anatolian Society of Medical Oncology.
Hepatogastroenterology
; 59(119): 2343-7, 2012 Oct.
Article
in En
| MEDLINE
| ID: mdl-22389301
ABSTRACT
BACKGROUND/AIMS:
The aims of this study were to report the clinical outcomes of adjuvant chemo-radiotherapy after curative resection in 637 patients with gastric cancer.METHODOLOGY:
The retrospective analysis included 637 patients with resectable gastric cancer and stage IB-IV (M0) from 8 medical centers between 2003 and 2010. The patients were treated with 5FU-leucovorin and radiotherapy according to Schema for INT-0116.RESULTS:
Of the 637 patients, the median of overall survival (OS) was 43.7 months and relapse free survival (RFS) was 36.6 months. OS rates were 84%, 45%, 40% while RFS rates were 81%, 45% and 35% at 1, 3 and 5-years, respectively. Hematological and gastrointestinal toxicities (grade 1-4) were observed in 35% and 36.5% of patients, respectively. In univariate analysis, according to the Lauren classification, tumor grade, T stage, N stage, type of operation (total gastrectomy or subtotal) and surgery resection margin (R0 or R1) were found as prognostic factors on RFS and OS (p<0.05). In multivariate analysis, T stage, N stage and surgical margins were found as effective factors on OS. T stage, N stage and Lauren classification were factors affecting RFS.CONCLUSIONS:
Adjuvant chemo-radiotherapy after curative resection of gastric cancer was feasible, with acceptable toxicities in the Turkish population.
Search on Google
Database:
MEDLINE
Main subject:
Stomach Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Chemoradiotherapy, Adjuvant
/
Gastrectomy
Type of study:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Country/Region as subject:
Asia
Language:
En
Journal:
Hepatogastroenterology
Year:
2012
Type:
Article
Affiliation country:
Turkey